This cohort study assesses the association of upfront peptide receptor radionuclide therapy (PRRT) vs upfront chemotherapy or targeted therapy with progression-free survival among patients in Italy with enteropancreatic neuroendocrine tumors… Click to show full abstract
This cohort study assesses the association of upfront peptide receptor radionuclide therapy (PRRT) vs upfront chemotherapy or targeted therapy with progression-free survival among patients in Italy with enteropancreatic neuroendocrine tumors who experienced disease progression after treatment with somatostatin analogues.
               
Click one of the above tabs to view related content.